Roy D. Baynes, M.D., Ph.D.

Roy D. Baynes, M.D., Ph.D. has served as a director of Travere Therapeutics since June 2016. Since July 2022, Dr. Baynes has served as executive vice president and chief medical officer of Eikon Therapeutics, Inc., a privately-held biotechnology company. Prior to Eikon, until April 2022 he served as senior vice president and head of global clinical development at Merck Research Laboratories, the research division of Merck and Co., Inc., commencing in December 2013 and as chief medical officer of Merck and Co, Inc., a global healthcare company, commencing in July 2016. Prior to his roles at Merck, Dr. Baynes served as senior vice president of oncology, inflammation and respiratory therapeutics at Gilead Sciences, Inc., a biopharmaceutical company, from January 2012 to December 2013. Prior to Gilead, Dr. Baynes held positions of increasing responsibility at Amgen Inc., a biotechnology company, including vice president of global clinical development and therapeutic area head for hematology/oncology. Before joining Amgen, Dr. Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center, at Wayne State University. Dr. Baynes has authored more than 150 publications and is a member or fellow of several international medical societies. Dr. Baynes currently serves on the board of directors of Natera, Inc., a genetic testing and diagnostics company, and on the board of directors of CatalYm GmbH, a privately-held Germany based biotechnology company. Previously he served on the board of directors of Atara Biotherapeutics, Inc., a T-cell immunotherapy company. Dr. Baynes received his medical degree and doctorate in philosophy from the University of the Witwatersrand in South Africa, and completed his medical training in the Department of Hematology and Oncology at Johannesburg Hospital.